The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: Systematic review and economic evaluation

Health Technology Assessment

Volumn 18, Issue 7, 2014, Pages 1-283

  Loveman, Emma ^a   Jones, Jeremy ^a   Clegg, Andrew J ^a   Picot, Joanna ^a   Colquitt, Jillian L ^a   Mendes, Diana ^a   Breen, David J ^b   Moore, Emily ^c   George, Steve ^b   Poston, Graeme ^d   Cunningham, David ^e   Ruers, Theo ^f   Primrose, John ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e ROYAL MARSDEN HOSPITAL   (United Kingdom)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION TECHNIQUES; AGED; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; GREAT BRITAIN; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84893473070     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18070     Document Type: Article

References (168)

1. Poste G, Fidler IJ. The pathogenesis of cancer metastasis. Nature 1980;283:139-46. http://dx.doi.org/10.1038/283139a0
2. Pritchard KI. Liver metastases: can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management? Eur J Cancer 1997;33(Suppl. 7): S11-14. http://dx.doi.org/10.1016/S0959-8049(97)90003-4
3. Kasper HU, Drebber U, Dries V, Dienes HP. [Liver metastases: incidence and histogenesis.] Z Gastroenterol 2005;43:1149-57.
4. Khan AN, MacDonald S, Pankhania A, Sherlock D. Liver Metastases 2009: URL: http://emedicine.medscape.com/article/369936-overview (accessed 7 February 2011).
5. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-10. http://dx.doi.org/10.1016/S0140-6736(94)92529-1
6. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 2000;321:531-5.
7. Warrell DA. Oxford Textbook of Medicine. Oxford: Oxford University Press; 2003.
8. Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006;244:254-9. http://dx.doi.org/10.1097/01.sla.0000217629.94941.cf
9. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 2006;93: 465-74. http://dx.doi.org/10.1002/bjs.5278
10. Kune GA, Kune S, Field B, White R, Brough W, Schellenberger R, et al. Survival in patients with large-bowel cancer. A population-based investigation from the Melbourne Colorectal Cancer Study. Dis Colon Rectum 1990;33:938-46. http://dx.doi.org/10.1007/BF02139103
11. Alley PG, McNee RK. Colorectal cancer in Auckland 1981-1982: patients with liver metastases. N Z Med J 1985;98:697-9.
12. Primrose JN, Fuller A, Rose P, Perera-Salazar R, Mellor J, Corkhill A, et al. Follow-up after colorectal cancer surgery: preliminary observational findings from the UK FACS trial. ASCO Meeting Abstracts 2011;29:3521.
13. Cancer Research UK. Bowel (colorectal) cancer UK incidence statistics. London: Cancer Research UK; 2011. URL: www.cancerresearchuk.org/cancer-info/cancerstats/types/bowel/incidence/uk-bowel-cancer-incidence-statistics.
14. Ruers TJ, Joosten JJ, Wiering B, Langenhoff BS, Dekker HM, Wobbes T, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007;14:1161-9. http://dx.doi.org/10.1245/s10434- 006-9312-5
15. Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006;94:982-99. http://dx.doi.org/10.1038/sj.bjc.6603033
16. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Br J Cancer 2012;4:283-301.
17. Garden OJ, Rees M, Poston GJ, Mirza D, Saunders M, Ledermann J, et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006;55(Suppl. 3):iii1-8. http://dx.doi.org/10.1136/gut.2006.098053
18. Oxford English Dictionary. Oxford English Dictionary. Oxford: Oxford University Press; 2011.
19. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD 3rd, Dupuy DE, et al. Imageguided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005;235:728-39. http://dx.doi.org/10.1148/radiol.2353042205
20. Evans J. Ablative and catheter-delivered therapies for colorectal liver metastases (CRLM). Eur J Surg Oncol 2007;33:S64-S75. http://dx.doi.org/10.1016/j.ejso.2007.09.027
21. Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol 2007;18:1469-78. http://dx.doi.org/10.1016/j.jvir.2007.08.027
22. Goldberg SN, Grassi CJ, Cardella JF, Charboneau JW, Dodd GD, Dupuy DE, et al. Image-guided tumor ablation: Standardization of terminology and reporting criteria. J Vasc Interv Radiol 2005;16:765-78. http://dx.doi.org/10.1148/radiol.2353042205
23. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9. http://dx.doi.org/10.1002/hep.22648
24. Australian Safety and Efficacy Register of New Interventional Procedures - Surgical. Electrolytic Ablation of Tumours. North Adelaide, SA: ASERNIP-S; 2002.
25. Gravante G, Ong SL, Metcalfe MS, Bhardwaj N, Maddern GJ, Lloyd DM, et al. Experimental application of electrolysis in the treatment of liver and pancreatic tumours: principles, preclinical and clinical observations and future perspectives. Surg Oncol 2011;20:106-20. http://dx.doi.org/10.1016/j.suronc.2009.12.002
26. Bhardwaj N, Strickland AD, Ahmad F, Dennison AR, Lloyd DM. Liver ablation techniques: a review. Surg Endosc 2010;24:254-65. http://dx.doi.org/10.1007/s00464-009-0590-4
27. Leen E, Horgan PG. Radiofrequency ablation of colorectal liver metastases. Surg Oncol 2007;16:47-51 http://dx.doi.org/10.1016/j.suronc.2007.04.004
28. National Institute for Health and Care Excellence. Cryotherapy for the treatment of liver metastases: IPG369. London: National Institute for Health and Care Excellence; 2010.
29. Dodd GD 3rd, Soulen MC, Kane RA, Livraghi T, Lees WR, Yamashita Y, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. Radiographics 2000;20:9-27.
30. Vogl TJ, Muller PK, Hammerstingl R, Weinhold N, Mack MG, Philipp C, et al. Malignant liver tumors treated with MR imaging-guided laser-induced thermotherapy: technique and prospective results. Radiology 1995;196:257-65.
31. Gillams AR, Lees WR. Survival after percutaneous, image-guided, thermal ablation of hepatic metastases from colorectal cancer. Dis Colon Rectum 2000;43:656-61. http://dx.doi.org/10.1007/BF02235582
32. Pacella CM, Valle D, Bizzarri G, Pacella S, Brunetti M, Maritati R, et al. Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: results of a phase II study. Acta Oncol 2006;45:77-83. http://dx.doi.org/10.1080/02841860500438029
33. Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, et al. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer 2010;10:545. http://dx.doi.org/10.1186/1471-2407-10-545
34. Vogl TJ, Mack MG, Eichler K, Zangos S, Naguib NN, Gruber-Rouh T. [Chemoperfusion and embolization in the treatment of liver metastases.] Rofo 2011;183:12-23.
35. Vogl TJ, Mack MG, Muller PK, Straub R, Engelmann K, Eichler K. Interventional MR: interstitial therapy. Eur Radiol 1999;9:1479-87. http://dx.doi.org/10.1007/s003300050874
36. National Institute for Health and Care Excellence. Microwave ablation for the treatment of liver metastases: IPG406. London: National Institute for Health and Care Excellence; 2011.
37. Lloyd DM, Lau KN, Welsh F, Lee KF, Sherlock DJ, Choti MA, et al. International multicentre prospective study on microwave ablation of liver tumours: preliminary results. HPB 2011; 13:579-85. http://dx.doi.org/10.1111/j.1477-2574.2011.00338.x
38. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd GD 3rd, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 2010;28:493-508. http://dx.doi.org/10.1200/JCO.2009.23.4450
39. Razafindratsira T, Isambert M, Evrard S. Complications of intraoperative radiofrequency ablation of liver metastases. HPB 2011;13:15-23. http://dx.doi.org/10.1111/j.1477-2574.2010.00243.x
40. National Institute for Health and Care Excellence. Radiofrequency ablation for the treatment of colorectal metastases in the liver - guidance: IPG092. London: National Institute for Health and Care Excellence; 2004.
41. ter Haar G, Coussios C. High intensity focused ultrasound: physical principles and devices. Int J Hyperthermia 2007;23:89-104. http://dx.doi.org/10.1080/02656730601186138
42. Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, et al. The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer 2005;93:890-5. http://dx.doi.org/10.1038/sj.bjc.6602803
43. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M, et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993;18:1121-6.
44. http://dx.doi.org/10.1016/0270-9139(93)90467-2
45. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995;22:522-6.
46. Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment. Eur J Pharm Sci 2011;44:1-10. http://dx.doi.org/10.1016/j.ejps.2011.06.013
47. Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 2011;34:37-49. http://dx.doi.org/10.1007/s00270-010-0012-y
48. Carter S, Martin Ii RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) 2009;11:541-50. http://dx.doi.org/10.1111/j.1477-2574.2009.00071.x
49. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009;6:687-97. http://dx.doi.org/10.1038/nrclinonc.2009.165
50. TheraSphere. TheraSphere. A Patient's Guide. Mont Saint-Guibert: Nordion; 2011. URL: www.therasphere.com (accessed 17 October 2011).
51. Sirtex Medical Limited. SIRTeX SIR-Spheres microspheres. Package Insert; 2010.
52. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009;19:951-9. http://dx.doi.org/10.1007/s00330-008-1211-7
53. Cabanillas M, Perez-Perez L, Sanchez-Aguilar D, Fernandez-Redondo V, Toribio J. [Acrokeratosis paraneoplastica with bullous lesions associated with esophageal squamous cell carcinoma.] Actas Dermosifiliogr 2006;97:196-9.
54. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005;16:1311-19. http://dx.doi.org/10.1093/annonc/mdi246
55. Jonker DJ, Maroun JA, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000;82:1789-94. http://dx.doi.org/10.1054/bjoc.1999.1254
56. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-16. http://dx.doi.org/10.1016/S0140-6736(08)60455-9
57. Fahy BN, Aloia TA, Jones SL, Bass BL, Fischer CP. Chemotherapy within 30 days prior to liver resection does not increase postoperative morbidity or mortality. HPB 2009;11:645-55. http://dx.doi.org/10.1111/j.1477-2574.2009.00107.x
58. Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-17. http://dx.doi.org/10.1097/01.SLA.0000048447.16651.7B
59. Adam R, Hagopian EJ, Linhares M, Krissat J, Savier E, Azoulay D, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137:1332-9; discussion 40. http://dx.doi.org/10.1001/archsurg.137.12.1332.
60. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H. Two-stage hepatectomy: a planned strategy to treat irresectable liver tumors. Ann Surg 2000;232:777-85. http://dx.doi.org/10.1097/00000658-200012000-00006.
61. Neeleman N, Andersson R. Repeated liver resection for recurrent liver cancer. Br J Surg 1996;83:893-901. http://dx.doi.org/10.1002/bjs.1800830705.
62. National Institute for Health and Care Excellence. Cetuximab for the first-line treatment of metastatic colorectal cancer: TA176. London: National Institute for Health and Care Excellence; 2009.
63. National Institute for Health and Care Excellence. Colorectal cancer: the diagnosis and management of colorectal cancer: CG131. London: National Institute for Health and Care Excellence; 2011. Ahmed N, Ahmedzai S, Vora V, Hillam S, Paz S. Supportive care for patients with gastrointestinal cancer. Cochrane Database Syst Rev 2004;3:CD003445. http://dx.doi.org/10.1002/14651858. CD003445.
64. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003;9:193-200.
65. Centre for Reviews and Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in health care. York: CRC, University of York; 2009.
66. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097. http://dx.doi.org/10.1371/journal.pmed.1000097.
67. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83. http://dx.doi.org/10.1136/bmj.313.7052.275.
68. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36). http://dx.doi.org/10.2165/00019053-200624040-00006.
69. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 (updated September 2009). The Cochrane Collaboration; 2009. URL: www.cochrane-handbook.org.
70. Mack MG, Straub R, Eichler K, Engelmann K, Zangos S, Roggan A, et al. Percutaneous MR imaging-guided laser-induced thermotherapy of hepatic metastases. Abdom Imaging 2001;26:369-74. http://dx.doi.org/10.1007/s002610000197.
71. Mack MG, Straub R, Eichler K, Sollner O, Lehnert T, Vogl TJ. Breast cancer metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004;233:400-9. http://dx.doi.org/10.1148/radiol.2332030454.
72. Shibata T, Niinobu T, Ogata N, Takami M. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer 2000;89:276-84. http://dx.doi.org/10.1002/1097-0142(20000715)89:2276::AID-CNCR113.3.CO;2-S
73. Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011;81:25-34. http://dx.doi.org/10.4174/jkss.2011.81.1.25.
74. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005;23:1358-64. http://dx.doi.org/10.1200/JCO.2005.12.039.
75. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann Surg Oncol 2008;15:2757-64. http://dx.doi.org/10.1245/s10434-008-0043-7.
76. Gillams AR, Lees WR. Radio-frequency ablation of colorectal liver metastases in 167 patients. Eur Radiol 2004;14:2261-7. http://dx.doi.org/10.1007/s00330-004-2416-z
77. Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009;19:1206-13. http://dx.doi.org/10.1007/s00330-008-1258-5.
78. Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 2007;246:559-65; discussion 65-7. http://dx.doi.org/10.1097/SLA.0b013e318155a7b6.
79. Solbiati L, Livraghi T, Goldberg SN, Ierace T, Meloni F, Dellanoce M, et al. Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-66. http://dx.doi.org/10.1148/radiol.2211001624.
80. Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol 2007;48:253-8. http://dx.doi.org/10.1080/02841850601161539
81. Taguchi T, Ogawa N, Bunke B, Nilsson B. The use of degradable starch microspheres (Spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumours - results of a phase III clinical trial. Regional Cancer Treatment 1992;4:161-5.
82. Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004;14:217-22. http://dx.doi.org/10.1097/01.cmr.0000129377.22141.ea
83. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 2003;229:457-64. http://dx.doi.org/10.1148/radiol.2292021329.
84. Vogl TJ, Naguib NN, Nour-Eldin NE, Mack MG, Zangos S, Abskharon JE, et al. Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer. AJR Am J Roentgenol 2011;196:W66-72. http://dx.doi.org/10.2214/AJR.09.3836.
85. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711-20.
86. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010;28:3687-94. http://dx.doi.org/10.1200/JCO.2010.28.5643.
87. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004;88:78-85. http://dx.doi.org/10.1002/jso.20141.
88. Van Hazel GA, Turner D, Gebski V. Impact of Y-90 resin microspheres on health-related quality of life (HRQoL) in patients with colorectal cancer (CRC) liver metastases receiving first-line chemotherapy. Alexandria, VA: American Society of Clinical Oncology; 2009. URL: http://meetinglibrary.asco.org/content/10692-63.
89. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol 1984;2:472-83.
90. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 1981; 34:585-97.
91. Ruers T, Van Coevorden F, Pierie J, Rinkes IB, Punt C, Lederman J, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Ann Oncol 2010;21:I41-I42.
92. Ruers T, Van Coevorden F, Pierie J, Borel-Rinkes I, Punt C, Ledermann J, et al. Radiofrequency ablation combined with chemotherapy for unresectable CRC liver metastases: interim results of a randomised phase II study (CLOCC) (EORTC-NCRI CCSG-ALM). Ann Oncol 2009;20:13.
93. Ruers T, Van Coevorden F, Pierie J, Borel-Rinkes I, Punt C, Ledermann J, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Interim results of a randomised phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Ann Surg Oncol 2009;16:3.
94. Ruers T, Punt CJ, Van Coevorden F, Borel-Rinkes I, Ledermann J, Poston GJ, et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). J Clin Oncol 2010;28(Suppl.; abstract 3526):15s.
95. Hirata M, Suzuki N, Miura Y, Katayama A, Tanaka Y, Tanaka K, et al. Effect of radio frequency ablation therapy for liver metastasis from colorectal cancer. 14th Congress of the European Society of Surgical Oncology, The Hague, the Netherlands, 10-12 September 2008.
96. Van Den Eynde M, Hendlisz A, Peeters M, Defreyne L, Maleux G, Vannoote J, et al. Prospective randomized study comparing hepatic intra-arterial injection of Yttrium-90 resin-microspheres (HAI-Y90) with protracted IV 5FU (5FU CI) versus 5FU CI alone for patients with liver-limited metastatic colorectal cancer (LMCRC) refractory to standard chemotherapy (CT). J Clin Oncol 2009;27(Suppl.):15s.
97. Fiorentini G, Aliberti C, Montagnani F, Tilli M, Mambrini A, Benea G. Trans-arterial chemoembolization of metastatic colorectal carcinoma (MCRC) to the liver adopting polyvinyl alcohol microspheres (PAM) loaded with irinotecan compared with Folfiri (CT): evaluation at two years of a phase III clinical trial. Ann Oncol 2010;21(Suppl. 8):191.
98. Fiorentini G, Aliberti C, Montagnani F, Tilli M, Mambrini A, Giannessi P, et al. First evaluation of phase III trial of tace adopting polyvinyl-alcohol microspheres (PAM) irinotecan (IRI) loaded vs Folfiri (CT) for non operable colorectal cancer (CRC) liver metastases. Ann Oncol 2009;20(Suppl. 7):14.
99. Jones R, Tang J, Pathak S, Parmar C, Fenwick S, Malik H, et al. Systematic review of ablation therapies for the treatment of unresectable colorectal liver metastases. 9th Congress of the European Hepato Pancreato Biliary Association, Cape Town, South Africa, 12-16 April 2011.
100. Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 2011;13:e252-65. http://dx.doi.org/10.1111/j.1463-1318.2011.02695.x
101. Australian Safety and Efficacy Register of New Interventional Procedures - Surgical. Radiofrequency Ablation of Liver Tumours (Update and Re-appraisal): A Systematic Review. Report no. North Adelaide, SA: ASERNIP-S; 2006.
102. Medical Services Advisory Committee (MSAC). Radiofrequency Ablation of Liver Tumours. Canberra, ACT: Commonwealth Department of Health and Ageing; 2003.
103. Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009;45:1748-56. http://dx.doi.org/10.1016/j.ejca.2009.03.012.
104. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141:181-90. http://dx.doi.org/10.1001/archsurg.141.2.181.
105. Medical Services Advisory Committee (MSAC). Selective Internal Radiation Therapy for Hepatic Metastases using SIR-Spheres. Canberra, ACT: Commonwealth Department of Health and Ageing; 2002.
106. Bergenfeldt M, Jensen BV, Skjoldbye B, Nielsen D. Liver resection and local ablation of breast cancer liver metastases - a systematic review. Eur J Surg Oncol 2011;37:549-57. http://dx.doi.org/10.1016/j.ejso.2011.04.013.
107. Smith MD, McCall JL. Systematic review of tumour number and outcome after radical treatment of colorectal liver metastases. Br J Surg 2009;96:1101-13. http://dx.doi.org/10.1002/bjs.6735
108. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR. Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev 2009;2:CD007060. http://dx.doi.org/10.1002/14651858.CD007060.pub2.
109. Gurusamy KS, Ramamoorthy R, Imber C, Davidson BR. Surgical resection versus non-surgical treatment for hepatic node positive patients with colorectal liver metastases. Cochrane Database Syst Rev 2010;1:CD006797. http://dx.doi.org/10.1002/14651858.CD006797.
110. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev 2008;1: CD006039. http://dx.doi.org/10.1002/14651858.CD006039.pub3.
111. McKay A, Kutnikoff T, Taylor M. A cost-utility analysis of treatments for malignant liver tumours: a pilot project. HPB (Oxford) 2007;9:42-51. http://dx.doi.org/10.1080/13651820600994541.
112. Shetty SK, Rosen MP, Raptopoulos V, Goldberg SN. Cost-effectiveness of percutaneous radiofrequency ablation for malignant hepatic neoplasms. J Vasc Interv Radiol 2001;12:823-33. http://dx.doi.org/10.1016/S1051-0443(07)61507-3.
113. Bonastre J, De Baere T, Elias D, Evrard S, Rouanet P, Bazin C, et al. Cost of radiofrequency ablation in the treatment of hepatic malignancies. Gastroenterol Clin Biol 2007;31:828-35. http://dx.doi.org/10.1016/S0399-8320(07)73973-8.
114. Grundmann RT. [Liver metastases of colorectal carcinoma - may the DRG-system influence the operative procedure?] Zentralbl Chir 2007;132:287-92.
115. Abramson RG, Rosen MP, Perry LJ, Brophy DP, Raeburn SL, Stuart KE. Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy. Radiology 2000;216:485-91.
116. Gazelle GS, McMahon PM, Beinfeld MT, Halpern EF, Weinstein MC. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Radiology 2004;233:729-39. http://dx.doi.org/10.1148/radiol.2333032052.
117. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Care Excellence; 2008.
118. Gazelle GS, Hunink MG, Kuntz KM, McMahon PM, Halpern EF, Beinfeld M, et al. Costeffectiveness of hepatic metastasectomy in patients with metastatic colorectal carcinoma: a state-transition Monte Carlo decision analysis. Ann Surg 2003;237:544-55. http://dx.doi.org/10.1097/01.SLA.0000059989.55280.33.
119. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993; 13:89-102. http://dx.doi.org/10.1177/0272989X9301300202.
120. Allen-Mersh TG, Earlam S, Fordy C, Abrams K, Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255-60. http://dx.doi.org/10.1016/S0140-6736(94)90750-1.
121. Earlam S, Glover C, Fordy C, Burke D, Allen-Mersh TG. Relation between tumor size, quality of life, and survival in patients with colorectal liver metastases. J Clin Oncol 1996;14:171-5.
122. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26. http://dx.doi.org/10.1093/jnci/87.6.417.
123. Burgdorf SK. Dendritic cell vaccination of patients with metastatic colorectal cancer. Dan Med Bull 2010;57:B4171.
124. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22:2395-403. http://dx.doi.org/10.1200/JCO.2004.08.154.
125. Coates A, Thomson D, McLeod GR, Hersey P, Gill PG, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993;29A:1731-4. http://dx.doi.org/10.1016/0959-8049(93) 90115-V
126. Conroy T, Uwer L, Deblock M. Health-related quality-of-life assessment in gastrointestinal cancer: are results relevant for clinical practice? Curr Opin Oncol 2007;19:401-6. http://dx.doi.org/10.1097/CCO.0b013e32816f7704.
127. Eid S, Stromberg AJ, Ames S, Ellis S, McMasters KM, Martin RC. Assessment of symptom experience in patients undergoing hepatic resection or ablation. Cancer 2006;107:2715-22. http://dx.doi.org/10.1016/j.jamcollsurg.2005.06.149.
128. Kavadas V, Blazeby JM, Conroy T, Sezer O, Holzner B, Koller M, et al. Development of an EORTC disease-specific quality of life questionnaire for use in patients with liver metastases from colorectal cancer. Eur J Cancer 2003;39:1259-63. http://dx.doi.org/10.1016/S0959-8049(03) 00236-3.
129. Lloyd Jones M, Hummel S, Bansback N, Orr B, Seymour M. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Health Technol Assess 2001;5(25).
130. Méndez Romero A, Wunderink W, van Os RM, Nowak PJCM, Heijmen BJM, Nuyttens JJ, et al. Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys 2008;70:1447-52. http://dx.doi.org/10.1016/j.ijrobp.2007.08.058.
131. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993;306:752-5. http://dx.doi.org/10.1136/bmj.306.6880.752.
132. Adams R, Wilson RH, Seymour MT, Meade AM, Madi A, Cassidy J, et al. Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) in first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial. J Clin Oncol 2010;28:3525.
133. Foss A, Andersen MH, Hagness M, Vidnes T, Finstad ED, Wahl AK, et al. Patient survival and quality of life following liver transplantation for colorectal liver metastases. Liver Transplantation 2010;16:S189-90. http://dx.doi.org/10.1097/00007890-201007272-01582.
134. Lorenz M, Hanisch E. [Quality of life and survival after continuous intrahepatic floxuridine infusions in liver metastases of colorectal carcinomas.] Z Gastroenterol 1995;33:679-80.
135. Borrego-Estella V, Montero-Martin J, Serrablo A. Quality of life of patients with liver metastases colorectal cancer. 9th Congress of the European Hepato Pancreato Biliary Association; Cape Town, South Africa; 12-16 April 2011.
136. Karuna ST, Thirlby R, Biehl T, Veenstra D. Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis. J Surg Oncol 2008;97:396-403. http://dx.doi.org/10.1016/j.jamcollsurg.2007.06.177.
137. Blair SL, Grant M, Chu DZ, Cullinane C, Dean G, Schwarz RE, et al. Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy. Ann Surg Oncol 2003;10:144-9 http://dx.doi.org/10.1245/ASO.2003.03.060
138. Blazeby JM, Fayers P, Conroy T, Sezer O, Ramage J, Rees M. Validation of the European Organization for Research and Treatment of Cancer QLQ-LMC21 questionnaire for assessment of patient-reported outcomes during treatment of colorectal liver metastases. Br J Surg 2009;96:291-8. http://dx.doi.org/10.1002/bjs.6471.
139. Bruns H, Kratschmer K, Hinz U, Brechtel A, Keller M, Buchler MW, et al. Quality of life after curative liver resection: a single center analysis. World J Gastroenterol 2010;16:2388-95. http://dx.doi.org/10.3748/wjg.v16.i19.2388.
140. Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, et al. Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Espanol Multidisciplinar en Cancer Digestivo (GEMCAD). Rev Recent Clin Trials 2011;6:158-70. http://dx.doi.org/10.2174/157488711795177868.
141. Cella D, Cappelleri JC, Bushmakin A, Charbonneau C, Li JZ, Kim ST, et al. Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa. J Oncol Pract 2009;5:66-70. http://dx.doi.org/10.1200/JOP.0922004.
142. Durand-Zaleski I, Earlam S, Fordy C, Davies M, Allen-Mersh TG. Cost-effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases. Cancer 1998;83:882-8. http://dx.doi.org/10.1002/(SICI)1097-0142(19980901)83:5882::AID-CNCR123.3.CO;2-S
143. Haidet P, Hamel MB, Davis RB, Wenger N, Reding D, Kussin PS, et al. Outcomes, preferences for resuscitation, and physician-patient communication among patients with metastatic colorectal cancer. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Am J Med 1998;105:222-9.
144. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006;24:1395-403. http://dx.doi.org/10.1200/JCO.2005.03.8166.
145. Knox CD, Feurer ID, Wise PE, Lamps LW, Kelly Wright J, Chari RS, et al. Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg 2004;8:653-9. http://dx.doi.org/10.1016/j.gassur.2004.04.003.
146. Krabbe PF, Peerenboom L, Langenhoff BS, Ruers TJ. Responsiveness of the generic EQ-5D summary measure compared to the disease-specific EORTC QLQ C-30. Qual Life Res 2004;13:1247-53. http://dx.doi.org/10.1023/B:QURE.0000037498.00754.b8.
147. Langenhoff BS, Krabbe PF, Peerenboom L, Wobbes T, Ruers TJ. Quality of life after surgical treatment of colorectal liver metastases. Br J Surg 2006;93:1007-14. http://dx.doi.org/10.1002/bjs.5387.
148. Pistevou-Gombaki K, Eleftheriadis N, Plataniotis GA, Sofroniadis I, Kouloulias VE. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Palliat Med 2003; 17:257-62. http://dx.doi.org/10.1191/0269216303pm698oa
149. Wiering B, Oyen WJ, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, et al. Long-term global quality of life in patients treated for colorectal liver metastases. Br J Surg 2011;98:565-71; discussion 71-2. http://dx.doi.org/10.1002/bjs.7365.
150. Wietzke-Braun P, Schindler C, Raddatz D, Braun F, Armbrust T, Nolte W, et al. Quality of life and outcome of ultrasound-guided laser interstitial thermo-therapy for non-resectable liver metastases of colorectal cancer. Eur J Gastroenterol Hepatol 2004;16:389-95. http://dx.doi.org/10.1097/00042737-200404000-00004.
151. Wiering B, Adang EM, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. Nucl Med Commun [Multicenter Study Randomized Controlled Trial] 2010;31:938-44. http://dx.doi.org/10.1097/MNM.0b013e32833fa9ba
152. Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG. Effect of regional and systematic fluorinated pyrimidine chemotherapy on quality of life in colorectal live metastasis patients. J Clin Oncol 1997;15:2022-9.
153. Chan JA, Kulke MH. Emerging therapies for the treatment of patients with advanced neuroendocrine tumors. Expert Opin Emerg Drugs 2007;12:253-70. http://dx.doi.org/10.1517/14728214.12.2.253.
154. Department of Health; Joint Surveys Unit of Social and Community Planning Research; Department of Epidemiology and Public Health UCL. Health Survey for England 1996. London: Department of Health; 1998.
155. Poon RT, Fan ST, Yu WC, Lam BK, Chan FY, Wong J. A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg 2001;136:693-9. http://dx.doi.org/10.1001/archsurg.136.6.693.
156. Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, et al. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2010;14(19).
157. Tappenden P, Chilcott J, Ward S, Eggington S, Hind D, Hummel S. Methodological issues in the economic analysis of cancer treatments. Eur J Cancer 2006;42:2867-75. http://dx.doi.org/10.1016/j.ejca.2006.08.010.
158. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: The Stationery Office; 2003
159. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making. Am J Med 1982;73:889-97.
160. Tappenden P, Jones R, Paisley S, Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007;11(12).
161. Petrou S., Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs 1997;3:275-80.
162. Department of Health. NHS Reference Costs 2009-2010: London: Department of Health; 2011. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459 (access date 13 January 2011).
163. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004;91:77-83. http://dx.doi.org/10.1038/sj.bjc.6601890.
164. Department of Health. NHS Reference Costs 2008-2009: London: Department of Health; 2010. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_111591 (access date 13 January 2011).
165. Curtis L. Unit Costs of Health and Social Care 2007. Canterbury: PSSRU, University of Kent; 2007.
166. Coyle D, Lee M. Evidence-based economic evaluation: how the use of different data sources can impact results. In Donaldson C, Mugford M, Vale L, editors. Evidence-based Health Economics: From Effectiveness to Efficiency in Ssystematic Rreviews. London: BMJ Books; 2002. pp. 55-66.
167. Heusner TA, Hamami ME, Ertle J, Hahn S, Poeppel T, Hilgard P, et al. Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization. Rofo 2010;182:603-8. http://dx.doi.org/10.1055/s-0029-1245192.
168. Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2008.